Postgrad LIVE! Study Fairs

Birmingham | Edinburgh | Liverpool | Sheffield | Southampton | Bristol

University of Manchester Featured PhD Programmes
University College London Featured PhD Programmes
University of Edinburgh Featured PhD Programmes
University of Oxford Featured PhD Programmes
University of Reading Featured PhD Programmes
United Kingdom
Leeds×
10 miles

Pharmacy / Pharmaceutics PhD Projects in Leeds

We have 18 Pharmacy / Pharmaceutics PhD Projects in Leeds

  • Pharmacy / Pharmaceutics×
  • United Kingdom×
  • Leeds×
  • PhD Research Project×
  • clear all
Order by 
Showing 1 to 10 of 18
  Pharmaceutical cocrystallisation for improved medicines
  Research Group: Medicines Development and Pharmaceutical Sciences
  Dr V Vangala, Prof A Paradkar
Applications accepted all year round
Active pharmaceutical ingredients (APIs) are frequently delivered to the patients in the solid-state formulation. Yet, therapeutic effectiveness of a dosage form depends on the bioavailability, stability and also on the manufacturability of the dosage form.
  Identifying glucose-dependent mechanisms underlying risk factors for Alzheimer’s disease
  Research Group: Pharmacology and Experimental Therapeutics
  Dr R Williamson, Dr S McLean
Applications accepted all year round
Several risk factors for Alzheimer’s disease including diabetes and midlife obesity are age-dependent and have an obvious metabolic component resulting in impaired glucose metabolism.
  Determining brain glycosylation in ageing and Alzheimer’s disease
  Research Group: Pharmacology and Experimental Therapeutics
  Dr R Williamson, Dr C Sutton
Applications accepted all year round
Increasing age is associated with lower levels of cognitive performance; concomitant with this is a decrease in brain glucose metabolism.
  Therapeutic resolution of pulmonary arterial hypertension (PAH) by natural products
  Research Group: Pharmacology and Experimental Therapeutics
  Dr T Nasim, Prof C Wright
Applications accepted all year round
Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disorder which, if left untreated, leads to heart failure and death.
  Re-purposing established drugs for the resolution of pulmonary arterial hypertension (PAH)
  Research Group: Pharmacology and Experimental Therapeutics
  Dr T Nasim, Prof T Palmer
Applications accepted all year round
Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disorder which, if left untreated, leads to heart failure and death.
  Tetrazines as Traceless Carriers for Polar Drugs
  Research Group: Medicines Development and Pharmaceutical Sciences
  Dr R Wheelhouse, Prof P Loadman
Applications accepted all year round
A recent invention in Bradford has identified a new carrier molecule that reduces the polarity of polar drugs.
  Studies on impact of co-former selection on physicochemical properties of crystalline active pharmaceutical complexes
  Research Group: Medicines Development and Pharmaceutical Sciences
  Dr K Paluch
Applications accepted all year round
Studies on the enhanced bioavailability profile of existing antibiotics are essential, considering growing bacterial resistance and increasing demand on cost-effective and safe antibacterial treatments.
  Quantitative structure/skin-permeation relationships (QSPeRs); an investigation of the relevance of parameters determined with biomembrane-mimicking systems for the predictability of drug partitioning into skin
  Research Group: Medicines Development and Pharmaceutical Sciences
  Dr X Liu, Prof D J Tobin
Applications accepted all year round
The transdermal route has many advantages over other routes for the delivery of drugs with systemic activity. These include the ease of use (and withdrawal in the occurrence of side-effects), avoidance of first-pass metabolism, and improved patient compliance.
  Prodrugs Activated by Tumour Microenvironment
  Research Group: Institute of Cancer Therapeutics
  Dr R Wheelhouse, Prof P Loadman, Prof R M Phillips
Applications accepted all year round
The anticancer drug temozolomide (TMZ), has been in the clinic for treating brain tumours for nearly 30 years. Despite its “Blockbuster” status, no other compounds of this class have reached clinical trial.
  Activity based proteomic probes for profiling CYP2W1 in cancer tissues
  Research Group: Institute of Cancer Therapeutics
  Dr C Sutton, Dr K Pors
Applications accepted all year round
Cytochromes P450 (CYPs) are a superfamily of mixed function oxidases of which CYP1-4 subfamily members are unique in their ability to oxidise drugs.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2018
All rights reserved.